Why Edgewise Therapeutics Stock Topped the Market on Tuesday
Key Points
She raised her price target by $11 per share.
In her view, the company's No. 1 pipeline drug has vast potential.
- 10 stocks we like better than Edgewise Therapeutics ›
A significant price target boost from an analyst at a prominent U.S. bank was the main catalyst behind Edgewise Therapeutics' (NASDAQ: EWTX) rise on the stock market on Tuesday. Investors were encouraged enough by the move to bid the biotech's share price up by more than 2%, handily beating the 0.3% rise of the benchmark S&P 500 index.
$11 improvement
The pundit behind the increase was Tessa Romero of JPMorgan Chase unit JPMorgan. Well before market open Tuesday, she raised her Edgewise price target to $45 per share from $34. She maintained her overweight (read: buy) recommendation on the stock.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
According to reports, the analyst feels that Edgewise has several investigational programs that could vault it ahead. Romero noted renewed interest in the company's EDG-7500, a novel pipeline drug targeting the heart disorder hypertrophic cardiomyopathy (HCM).
In what surely isn't a coincidence, last week Edgewise published long-term data from an open-label study of muscular dystrophy treatment sevasemten. The data showed that patients suffering from one type of muscular dystrophy, Becker, showed stabilization of function when administered the drug.
This, the company wrote, is "in marked contrast to the functional decline expected from Becker natural history data."
Double dose
It's impressive when a biotech has only one high-potential medicine in advanced development; Edgewise has two. What's more, it's developing another two in the high-demand cardiovascular segment. All this makes the company a standout in the biotech sector and an exciting business to watch.
Should you buy stock in Edgewise Therapeutics right now?
Before you buy stock in Edgewise Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Edgewise Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $513,407!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,237!*
Now, it’s worth noting Stock Advisor’s total average return is 938% — a market-crushing outperformance compared to 188% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 17, 2026.
JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy.
Recommended Articles
